ARQT — Q4 FY25 Earnings Review (WSM)

Date: 2026-04-06 Quarter: Q4 FY25 (Dec-2025) | Reported: 2026-02-25 Price: ~22.54|Marketcap: 3.06B | EV: ~$2.94B

Verdict

This is a beat-and-raise from a company achieving profitability inflection ahead of schedule. Net product revenue of $127.5M (+84% YoY, +31% QoQ) re-accelerated sequentially after two quarters of moderating QoQ growth, operating margin swung from -10.6% to +14.2% YoY, and OCF hit $26.2M — the first meaningfully positive quarter, well ahead of management's own timeline. FY2026 guidance raised $25M to $480-495M, conservative against a Q4 annualized run-rate of $510M. Incremental operating margin of 44.8% confirms the business model scales beautifully.

I haven't written about ARQT before, but applying my framework: this hits multiple green flags simultaneously — FCF inflection, operating leverage kicking in, sequential re-acceleration at scale, and management underpromise/overdeliver on guidance. The binding constraints remain single-molecule concentration and the ~2030 patent cliff.

Thesis: Intact / Strengthening | Conviction: 3/5 | Action: Watchlist — would add on pullback to ~5x run-rate revenue (~$19)

The Numbers

12-Quarter Revenue Grid

| | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | | | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---| | Revenue ($m) | 2.8 | 5.2 | 38.1 | 13.5 | 49.6 | 30.9 | 44.8 | 71.4 | 65.8 | 81.5 | 99.2 | **129.5** | | QoQ % | -6.7% | +85.7% | +633% | -64.6% | +267% | -37.7% | +45.0% | +59.4% | -7.8% | +23.9% | +21.7% | **+30.5%** | | YoY % | -- | -- | -- | -- | +1671% | +494% | +17.6% | +429% | +32.7% | +164% | +121% | **+81.4%** | | Net Prod Rev ($m) | -- | -- | -- | -- | -- | -- | -- | 69.4 | 63.8 | 79.5 | 97.2 | 127.5 | | NP Rev QoQ % | -- | -- | -- | -- | -- | -- | -- | -- | -8.1% | +24.6% | +22.3% | +31.2% |

FY23-FY24 data is lumpy — that's FDA-driven revenue step-functions (approvals, launches). FY25 is the first normalized year. And it's the FY25 QoQ trend that matters:

FY25 Sequential Trend (Net Product Revenue)

The re-acceleration from +22.3% to +31.2% in Q4 is a green flag. Q4 had seasonal tailwinds (dermatology prescribing peak pre-holiday, new insurance deductibles), but the magnitude exceeded both the seasonal and the trend. The $30.3M sequential add is the largest in company history.

Margin Trajectory

| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---| | Gross Margin % [GAAP] | 93.3% | 88.7% | 87.7% | 90.3% | 86.6% | 90.8% | 91.2% | 91.0% | | Op Margin % [GAAP] | -63.7% | -162.1% | -87.3% | -10.6% | -37.2% | -17.9% | +8.6% | +14.2% | | Net Margin % [GAAP] | -71.4% | -169.3% | -92.6% | -15.1% | -38.1% | -19.5% | +7.5% | +13.4% | | FCF Margin % | -63.7% | -146.3% | -77.5% | -1.0% | -47.1% | +0.4% | -1.8% | +20.2% |

Four observations:

1. Gross margin has stabilised at ~91%. Six consecutive quarters above 87%. This is pharma-grade gross margin — cost of sales is negligible (~9% of revenue). No degradation from mix, pricing, or GTN.

2. Operating margin went from -10.6% to +14.2% in one year. That's a 24.8pp swing. Two consecutive GAAP-profitable quarters (Q3 +8.6%, Q4 +14.2%). The trajectory is unmistakable.

3. The incremental operating margin tells the real story:

   • Incremental revenue (Q4 FY25 vs Q4 FY24): $129.5M - 71.4M = **58.1M**
   • Incremental operating income: 18.4M − (−7.6M) = $26.0M
   • Incremental operating margin: 44.8% -> This is the long-term margin the business will converge to as revenue scales. Outstanding.

4. FCF margin of 20.2% in Q4 is remarkable for a company that was burning -247M/yearincashjusttwoyearsago(FY2023).OCFof+26.2M vs -$0.7M in Q4 FY24. Management's "ahead of schedule" characterisation is accurate — I expected the OCF inflection in Q1 FY26, not Q4 FY25.

Operating Leverage (Q4 FY25 vs Q4 FY24)

Revenue growing 81% while SG&A grows 37% and R&D grows 41%. That's the operating leverage playbook. SG&A still 61% of revenue tells you there's a long runway for further margin expansion as the top line scales toward $500M+.

Cash Flow & Balance Sheet

Net cash of $112.3M. No dilutive equity raise needed. Manageable debt (SLR term loan, maturity Aug 2029).

Yellow flag: trade receivables doubled. $146.2M = 1.13x quarterly revenue (vs 1.03x a year ago). Could be timing of payer collections or channel stocking. Management didn't flag it — which means either it's normal scaling or they're hoping nobody asks. Need Q1 FY26 to see if this normalises.

SBC & Dilution

Annual dilution of 2.6% is clean. SBC declining as % of revenue is exactly what you want. Full-year FY25 SBC of $40.4M vs revenue of $376M = 10.7%. Trending toward sub-8% in FY26.

Leading Indicators

No bearish divergence. All demand indicators align with or exceed revenue growth. The prescription volume growing 99% YoY while net product revenue grew 84% YoY means pricing dynamics are healthy (slight volume-to-revenue gap from GTN mix, not a concern).

The key leading indicator for pharma is prescription volume trend. Weekly Rxs at ~22,000 (+19% QoQ, +99% YoY) suggest Q1 FY26 revenue should be strong even with seasonal moderation.

Kowa transition is the wildcard. Kowa partnership terminated after 18 months -> replaced by 30-rep internal pilot. Unproven. Q1-Q2 FY26 results will reveal whether this was a smart move or a stumble. The primary care channel is ~150,000 potential prescribers vs ~25,000 dermatologists — huge TAM but much harder to penetrate.

Guidance Assessment

Guide looks conservative. Q4 annualized run-rate = $129.5M x 4 = 518M, whichexceedstheguidemidpoint(487.5M) by $30.5M. Even accounting for Q1 seasonality (call it 115 − 120M), theremainingQ2 − Q4needonlyaverage 122-127M to hit the midpoint. That's below Q4 FY25's level.

Management has established a beat-and-raise cadence: raised FY26 guide by $25M before FY26 even started. That's the "guide de-risked" pattern — management sandbagging slightly to create a setup for consistent beats. This is a bullish setup.

Prior Beliefs / Updated Beliefs

Prior Beliefs

This is my first analysis of ARQT, so no specific prior. Applying my framework cold, entering the quarter I would have expected:

• Revenue ~$120-125M (seasonal Q4 boost, trending up from Q3's $99.2M)
• Gross margin ~91% (stable)
• Operating margin ~10-12% (improvement from Q3's 8.6%)
• OCF roughly breakeven to slightly positive
• FY26 guidance either maintained or modest $5-10M raise

Updated Beliefs

The OCF magnitude was the biggest surprise. +26.2MinaquarterwhereI^′dhaveexpected 0-5M. This tells me the cost structure is now firmly below the revenue capacity of the business.

Valuation (Run-Rate)

Price ~22.54|Dilutedshares135.6M|Marketcap 3.06B | EV ~$2.94B

Assessment: Fair value. Not cheap, not stretched. For an 81% YoY grower with 91% gross margins, GAAP profitability, and an FCF inflection, 5.9x run-rate revenue is reasonable in specialty pharma. Compare to mature specialty pharma at 3-5x and high-growth pharma at 6-10x — ARQT sits right where it should.

The P/E of 43.9x on run-rate looks expensive, but margins are still early in their expansion arc. If FY26 operating margin reaches 18-20% (very achievable: Q4 was 14.2% and improving), FY26 net income could be $75-85M -> forward P/E drops to 36-41x. On 30% growth, that's a PEG of 1.2-1.4. Acceptable for a company with this margin trajectory.

I'd buy aggressively at 5x run-rate revenue (~$19) or on any pipeline de-risking event (pediatric PsO approval, infant AD sNDA).

Where I Diverge from Atlas

Atlas scored this 3/5 conviction with "Hold / Watchlist." I agree with the score but with different emphasis:

1. Atlas treats ~30% FY26 growth as a binding constraint. I weight the QoQ re-acceleration more heavily. In pharma, each new indication creates a step-function revenue acceleration. Pediatric PsO (PDUFA June 2026) + infant AD (sNDA Q2 2026) could re-accelerate growth above 30% in H2 FY26. Atlas's concern is valid for SaaS where deceleration is often terminal — in pharma it's not, because new approvals restart the growth engine.

2. Incremental operating margin. Atlas mentions operating leverage but doesn't quantify the incremental margin explicitly. 44.8% incremental operating margin is the number that matters most for modelling the path to peak profitability. It tells you that each dollar of additional revenue drops ~$0.45 to the operating line. At $500M revenue, that implies 25%+ operating margins are achievable at scale.

3. Valuation upside scenario. Management targets peak sales of 2.6 − 3.5Bvsanalystconsensusof 1.69B. Even at the low end ($2.6B), 20% operating margin, 15x P/E -> $7.8B market cap = $57/share (2.5x upside from here). This is a real scenario if the pediatric + vitiligo + HS programs work and the platform extends.

Key Risks

1. Single-molecule concentration. 95%+ revenue from roflumilast. Any safety signal, manufacturing issue, or competitive entry hits the whole franchise.
2. Patent cliff ~2030. Generic entry in ~4 years. Investors will begin applying a terminal value discount as 2028 approaches.
3. Growth deceleration to ~30%. FY25 was +91%. FY26 guide is ~30%. Growth investors may exit below the 40% threshold.
4. Trade receivables. $146.2M (1.13x quarterly revenue). If this doesn't normalise in Q1 FY26, it's a red flag on revenue quality.
5. Primary care execution. Kowa failed after 18 months. Internal pilot is unproven.

Key Catalysts

1. Pediatric PsO PDUFA — June 29, 2026. Binary regulatory event.
2. Infant AD sNDA — Q2 2026. 58% EASI-75 in Phase III.
3. Q1 FY26 earnings. First test of positive OCF commitment.
4. FY26 guidance beat potential. Run-rate (518M) > guidemidpoint(487.5M) by $30.5M.
5. Vitiligo Phase II data — Q4 2026. TAM expansion.

Thesis

Arcutis is executing a textbook commercial launch in specialty dermatology. ZORYVE is the #1 branded non-steroidal topical across 3 indications with 45% market share, 91% gross margins, and the company has reached GAAP profitability + FCF generation ahead of schedule. The commercial infrastructure (160 derm reps, 30 PC/peds pilot reps, >80% commercial payer access) is in place to compound from here.

What keeps conviction at 3/5: Single-molecule risk, ~2030 patent cliff, and growth deceleration to ~30% guided.

What would raise conviction to 4/5: (a) Pediatric PsO approval (June 2026) + demonstrated revenue uplift, (b) vitiligo Phase II positive data (Q4 2026) confirming platform extension, or (c) 2+ consecutive quarters of FY26 guidance raises.

What would break the thesis: Miss-and-lower on FY26 guidance, GTN deterioration below 50%, safety signal on roflumilast, or competitive entry that erodes market share.

Next earnings: Q1 FY26 (quarter ending Mar-2026), expected ~mid-May 2026. Management warned Q1 revenue will be lower than Q4's $127.5M due to typical seasonality. The number to watch: can they demonstrate positive OCF in a seasonally weak quarter?

-wsm

(No position in ARQT)